Site-Specific Drug Delivery | 2 Mers Seas Zeeën

Site Drug

You are here

Site-Specific Drug Delivery

Priority Axis

Technological and Social Innovation

Specific objective

Technological Innovation

Lead partner

Université de Lille

Start Date


End Date


Project budget

4 885 143

ERDF amount

2 931 086

ERDF rate



    Common challenge

    The large majority of drug products available on the market deliver the drug in a non-targeted manner into the human body: The drug is circulated via the blood throughout the entire organism. Parts of it reach the target site (e.g., a specific organ). However, the large majority of the administered drug dose is distributed within the rest of the body. Importantly, this drug is not only “lost” for the treatment, it is often harmful for the patient, causing potentially severe side effects. The latter have 3 major consequences, they: (1) constitute a major health burden for the patient (e.g. causing nausea, headache, cardiovascular complications), (2) can limit the drug dose that can be given to the patient, leading to nonoptimal therapeutic effects (the drug amount reaching the target site cannot be further increased), and (3) cause considerable costs for the health care systems (e.g., due to the treatment of side effects, prolonged hospitalisation times
    and sub-optimal treatments).



    University of Cambridge

    Universiteit Gent

    Technische Universiteit Delft

    Lattice Medical

    University College London


    Universiteit Leiden

    Société d'Accélération du Transfert de Technologie, Nord

    Centre Hospitalier Régional Universitaire de Lille